Download: Drug developers to watch – companies with ADCs in clinical development

With ADCs regularly cited as the hot topic of the antibody sector (and as perhaps focus moves away a little from traditional therapeutic mAbs) we're seeing more and more ADCs enter clinical development. Historically, only 3 ADCs have ever gained marketing approval – with the first, Pfizer's Gemtuzumab ozogamicin (Mylotarg) being withdrawn from market in June 2010. That leaves two …